Many studies have revealed the association between haptoglobin (Hp) and various infections and diseases, such as cancer, diabetes and cardiovascular diseases. CD BioGlyco is committed to developing rapid and robust methods for the detection of Hp, providing powerful tools for clinical diagnosis.
Hp is an acute-phase protein and any inflammatory process (infection, burns, extreme stress, allergies, severe crush injuries, etc.) may increase plasma haptoglobin levels. Hp is often used as a predictor of human diseases such as ovarian cancer, diabetes, certain neurological and cardiovascular diseases. In the clinical setting, Hp detection is commonly used to diagnose and monitor hemolytic anemia. In intravascular hemolysis, free hemoglobin is released into the circulation and therefore Hp binds to the hemoglobin. This causes a decrease in Hp levels.
Hp is also a predicting diagnostic biomarker commonly used to predict animal diseases such as mastitis, which is a recurrent disease in the dairy industry. The spread of pathogens causing mastitis and the long-term decline in milk production and quality have caused major economic challenges to the global dairy industry. The detection of HP is helpful for the early diagnosis of mastitis, which may have a positive impact on the individual health of animals.
Fig.1 Schematic illustration of the CL bioassay concept for Hp detection. (Fatima, 2019)
CD BioGlyco has developed multiple rapid and sensitive sensor-based assays for measuring Hp concentrations in mastitis milk. The Strategies we provide include but are not limited to:
CD BioGlyco has accumulated extensive experience in glyco-biomarker Hp detection. We provide our clients with high-quality services at competitive prices and within a short time frame. With our efficient strategies, customers could accelerate their scientific research. If you are interested in our services, please contact us for further information.